STOCK TITAN

89bio to Present at the 42nd Annual Raymond James Institutional Investors Conference

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary

89bio, a clinical-stage biopharmaceutical company, announced it will provide a corporate update and engage in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on March 3, 2021, at 12:30 PM ET. The presentation will be accessible via the conference portal. 89bio focuses on therapies for liver and cardio-metabolic diseases, with its lead product BIO89-100 targeting NASH and severe hypertriglyceridemia.

Positive
  • None.
Negative
  • None.

SAN FRANCISCO, Feb. 24, 2021 (GLOBE NEWSWIRE) -- 89bio, Inc. (Nasdaq: ETNB), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases, today announced that Company’s Management will provide a corporate update and participate in one-on-one investor meetings at the Raymond James 42nd Annual Institutional Investors Conference on Wednesday, March 3, 2021 at 12:30 PM ET.

The presentation will be available through the Raymond James conference portal and an archived webcast will also be accessible in the investor section of 89bio’s website.

About 89bio
89bio is a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of liver and cardio-metabolic diseases. The company’s lead product candidate, BIO89-100, is a specifically engineered glycoPEGylated analog of FGF21. BIO89-100 is being developed for the treatment of nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia (SHTG). 89bio is headquartered in San Francisco with operations in Herzliya, Israel.

Investor Contact:
Ryan Martins
Chief Financial Officer
investors@89bio.com

Media Contact:
Peter Duckler
773-343-3069
pduckler@w2ogroup.com


FAQ

When is the 89bio corporate update at the Raymond James conference?

The corporate update for 89bio is scheduled for March 3, 2021, at 12:30 PM ET.

How can I access 89bio's presentation at the conference?

The presentation can be accessed through the Raymond James conference portal.

What is BIO89-100 from 89bio?

BIO89-100 is a glycoPEGylated analog of FGF21, developed for treating nonalcoholic steatohepatitis (NASH) and severe hypertriglyceridemia.

What disease areas does 89bio focus on?

89bio focuses on the development of therapies for liver and cardio-metabolic diseases.

What is the stock symbol for 89bio?

The stock symbol for 89bio is ETNB.

89bio, Inc.

NASDAQ:ETNB

ETNB Rankings

ETNB Latest News

ETNB Stock Data

856.97M
106.13M
0.64%
101.13%
5.08%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
SAN FRANCISCO